Product Overview
The DRI® Benzodiazepine Assay is a homogeneous enzyme immunoassay intended for the qualitative and/or semi-quantitative determination of the presence of benzodiazepines and their metabolites in human urine at a cutoff concentration of 200 ng/mL
Product Features
- Qualitative or semi-quantitative options for results
- Excellent correlation to GC/MS
- These liquid, ready-to-use assays offer applications for an array of clinical chemistry analyzers and have been field-tested on a wide range of analyzers
- The semi-quantitative mode is for the purpose of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Liquid Chromatography/tandem mass spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures
Product Specifications
| Catalog Number/SKU | MF-5390012202 |
| Application | Toxicology Reagent |
|---|---|
| For Use With | For MedTest 200 Ensemble, 480 Ensemble and 800 Ensemble Systems |
| Form | Liquid |
| Sample Type | Urine Sample |
| Specialty | Toxicology |
| Storage Requirements | Requires Refrigeration |
| Test Category | Drugs of Abuse |
| Test Method | Homogeneous Enzyme Immunoassay (HEIA) |
| Test Name | Benzodiazepine (BZO) |
| Test Type | Single Drug |
| UNSPSC Code | 41116007 |
| Volume | 2 X 100 mL |
